OSU-2S TFA
Based on 1 publication(s) in Google Scholar
OSU-2S TFA is a non-immunosuppressive derivative of Fingolimod hydrochloride (FTY720) (HY-12005). It is an orally active, blood-brain barrier-permeable allosteric activator of PP2A that also activates PKCδ; it restores PP2A activity by displacing the inhibitory protein SET, thereby inducing ROS-PKCδ-caspase-3-dependent apoptosis, c-Myc degradation, cell cycle arrest, and differentiation. OSU-2S TFA is used in research on diseases such as leukemia, liver cancer, lymphoma, and lung cancer.
For research use only. We do not sell to patients.
- Formula: C23H38F3NO4
- Molecular Weight:449.55
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) OSU-2S TFA
More
Biological Activity
Description
|
PKCδ |
In Vitro
OSU-2S TFA activates PP2A in CLL cells[4].
OSU-2S TFA (5-24 h)-induced pSHP1 S591 levels correlate with CLL cell death[4].
OSU-2S TFA (8 μM; 4 h) activates PKC in CLL cells[4].
OSU-2S TFA (8 μM; 16-24 h) downregulates TCL1A expression in CLL[4].
OSU-2S TFA (5 μM; 24 h) selectively kills CLL cells without killing normal B cells via ROR1-targeted delivery[4].
OSU-2S TFA (2-8 μM; 24 h) exhibits strong cytotoxicity against MCL cell lines[3].
OSU-2S TFA (4-5 μM; 24 h) induces CD74 surface expression in MCL cells[3].
OSU-2S TFA (4 μM; 24 h) enhances the cytotoxicity of Milatuzumab (HY-P99731) against MCL by upregulating CD74[3].
OSU-2S TFA (2-10 μM; 48 h) exhibits antiproliferative activity against multiple HCC cell lines[2].
OSU-2S TFA (1.25-2.5 μM; 48 h) enhances the antiproliferative effect of Sorafenib (HY-10201) on HCC cells and exhibits a synergistic effect[2].
OSU-2S TFA (1.25-2.5 μM; 48 h) enhances the anti-HCC effect of Sorafenib through the PKCδ and ERK pathways[2].
OSU-2S TFA (1.25-2.5 μM; 8-24 h) in combination with Sorafenib inhibits HCC cell migration and invasion[2].
OSU-2S TFA (1.25-7.5 μM) activity against HCC cells is influenced by p53 status, and p53 restoration enhances sensitivity[2].
OSU-2S TFA (1-10 μM; 24 h) inhibits A549 proliferation with an IC50 of 4.432 μM[1].
OSU-2S TFA (1.5-6 μM; 14 days) inhibits colony formation in A549 cells[1].
OSU-2S TFA (1.5-6 μM; 12-24 h) inhibits A549 cell migration[1].
OSU-2S TFA (1.5-6 μM; 24 h) downregulates p-AURKA and S1PR1 protein expression in A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Canine B-cell lymphoma cell lines CLBL-1 and 17-71
-
Concentration:2 μM; 4 μM; 6 μM
-
Incubation Time:24 h
-
Result:Promoted cytotoxicity at concentrations as low as 2 μM.
-
Cell Line:Primary cells from canine spontaneous B-cell lymphoma
-
Concentration:2 μM; 4 μM; 8 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in canine lymphoma cells.
-
Cell Line:Primary CD19+ cells from CLL patients
-
Concentration:2 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in primary CLL cells.
-
Cell Line:CLL cells
-
Concentration:8 μM
-
Incubation Time:16 h
-
Result:Reduced TCL1A mRNA levels.
-
Cell Line:CLL cells
-
Concentration:8 μM
-
Incubation Time:24 h
-
Result:Reduced TCL1A protein levels.
-
Cell Line:MCL cell line
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in MCL cell lines.
-
Cell Line:Huh7, Hep3B, PLC5, HepG2
-
Concentration:2 μM; 4 μM; 6 μM; 8 μM; 10 μM
-
Incubation Time:48 h
-
Result:Inhibited cell proliferation, with HepG2 being the most sensitive.
-
Cell Line:A549
-
Concentration:1.5 μM; 3 μM; 6 μM
-
Incubation Time:12 h; 24 h
-
Result:Reduced the migration ability of A549 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Subcutaneous inoculation of A549 cells into BALB/c nude mice[1]
-
Dosage:2.5 mg/kg, 5 mg/kg, 10 mg/kg
-
Administration:i.p.; every other day for 35 days
-
Result:Tumor volume and weight were significantly reduced.
There was no significant decrease in mouse body weight.
Immunohistochemistry showed that OSU-2S downregulated Ki-67 and VEGF.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- ROS/oxidative-stress fluorescent staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Liver Cancer Modeling
Chemical Information
-
Appearance Solid
-
Molecular Weight 449.55
-
Formula C23H38F3NO4
-
SMILES
CCC[C@@](CCC1=CC=C(OCCCCCC(C)C)C=C1)(N)CO.O=C(O)C(F)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Osthole alleviates neuropathic pain by suppressing astrocytes activation and associated inflammatory responses via the PKCδ/TRPV4 signaling pathway. [Abstract]2025 Sep 10:165:115453. PMID: 40934539
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (222.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2244 mL | 11.1222 mL | 22.2445 mL | 55.6112 mL |
| 5 mM | 0.4449 mL | 2.2244 mL | 4.4489 mL | 11.1222 mL | |
| 10 mM | 0.2224 mL | 1.1122 mL | 2.2244 mL | 5.5611 mL | |
| 15 mM | 0.1483 mL | 0.7415 mL | 1.4830 mL | 3.7074 mL | |
| 20 mM | 0.1112 mL | 0.5561 mL | 1.1122 mL | 2.7806 mL | |
| 25 mM | 0.0890 mL | 0.4449 mL | 0.8898 mL | 2.2244 mL | |
| 30 mM | 0.0741 mL | 0.3707 mL | 0.7415 mL | 1.8537 mL | |
| 40 mM | 0.0556 mL | 0.2781 mL | 0.5561 mL | 1.3903 mL | |
| 50 mM | 0.0445 mL | 0.2224 mL | 0.4449 mL | 1.1122 mL | |
| 60 mM | 0.0371 mL | 0.1854 mL | 0.3707 mL | 0.9269 mL | |
| 80 mM | 0.0278 mL | 0.1390 mL | 0.2781 mL | 0.6951 mL | |
| 100 mM | 0.0222 mL | 0.1112 mL | 0.2224 mL | 0.5561 mL |
OSU-2S TFA Related Classifications
HY-117720A Related Classifications
Powered by Bioz